Class action certified in US investor lawsuit against Wyeth/Pfizer over Pristiq
This article was originally published in Scrip
Executive Summary
US District Court Judge Richard Sullivan granted class action status for a lawsuit that alleges Wyeth misled investors about the safety of depression drug Pristiq (desvenlafaxine), causing the company's stock price to tumble when the US FDA issued a negative "approvable letter" regarding the treatment of vasomotor symptoms associated with menopause.